Drug-resistant juvenile myoclonic epilepsy: Misdiagnosis of progressive myoclonus epilepsy

  • Juvenile myoclonic epilepsy (JME) is a common epilepsy syndrome characterized by bilateral myoclonic and tonic-clonic seizures typically starting in adolescence and responding well to medication. Misdiagnosis of a more severe progressive myoclonus epilepsy (PME) as JME has been suggested as a cause of drug-resistance. Medical records of the Epilepsy Center Hessen-Marburg between 2005 and 2014 were automatically selected using keywords and manually reviewed regarding the presence of a JME diagnosis at any timepoint. The identified patients were evaluated regarding seizure outcome and drug resistance according to ILAE criteria. 87/168 identified JME patients were seizure-free at last follow-up including 61 drug-responsive patients (group NDR). Seventy-eight patients were not seizure-free including 26 drug-resistant patients (group DR). Valproate was the most efficacious AED. The JME diagnosis was revised in 7 patients of group DR including 6 in whom the diagnosis had already been questioned or revised during clinical follow-up. One of these was finally diagnosed with PME (genetically confirmed Lafora disease) based on genetic testing. She was initially reviewed at age 29 yrs and considered to be inconsistent with PME. Intellectual disability (p = 0.025), cognitive impairment (p < 0.001), febrile seizures in first-degree relatives (p = 0.023) and prominent dialeptic seizures (p = 0.009) where significantly more frequent in group DR. Individuals with PME are rarely found among drug-resistant alleged JME patients in a tertiary epilepsy center. Even a very detailed review by experienced epileptologists may not identify the presence of PME before the typical features evolve underpinning the need for early genetic testing in drug-resistant JME patients.

Download full text files

Export metadata

Metadaten
Author:Sarah Martin, Adam StrzelczykORCiDGND, Silvia Lindlar, Kristina Krause, Philipp Sebastian Reif, Katja Menzler, Andreas G. ChiocchettiORCiDGND, Felix RosenowORCiDGND, Susanne KnakeORCiDGND, Karl Martin Klein
URN:urn:nbn:de:hebis:30:3-525415
DOI:https://doi.org/10.3389/fneur.2019.00946
ISSN:1664-2295
Pubmed Id:https://pubmed.ncbi.nlm.nih.gov/31551911
Parent Title (English):Frontiers in neurology
Publisher:Frontiers Research Foundation
Place of publication:Lausanne
Contributor(s):Edoardo Ferlazzo
Document Type:Article
Language:English
Year of Completion:2019
Date of first Publication:2019/09/10
Publishing Institution:Universitätsbibliothek Johann Christian Senckenberg
Release Date:2019/12/23
Tag:Lafora disease; epilepsy; genetics; juvenile myoclonic epilepsy; pharmacoresistance; progressive myoclonus epilepsy
Volume:10
Issue:Art. 946
Page Number:6
First Page:1
Last Page:6
Note:
Copyright © 2019 Martin, Strzelczyk, Lindlar, Krause, Reif, Menzler, Chiocchetti, Rosenow, Knake and Klein. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
HeBIS-PPN:458140333
Institutes:Medizin / Medizin
Dewey Decimal Classification:6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit
Sammlungen:Universitätspublikationen
Open-Access-Publikationsfonds:Medizin
Licence (German):License LogoCreative Commons - Namensnennung 4.0